Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study

The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years

Inclusion Criteria:

• At least 18 years of age
• Written informed consent obtained prior to study entry

Exclusion Criteria:

• Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
• History of any previous JE vaccination (e.g. JE-VAX®)
• Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
• A family history of congenital or hereditary immunodeficiency
• History of autoimmune disease
• Any acute infections within 2 weeks prior to enrollment
• Known or suspected HIV Infection
• Pregnancy, lactation or unreliable contraception in female subjects